As streptozotocin (STZ) selectively targets and kills pancreatic beta cells, it is widely used as an agent to induce Type 1 Diabetes Mellitus (T1DM). STZ models of T1DM are used for assessing mechanisms, screening treatments, and evaluating therapeutic approaches directed at diabetic complications.
Implantable telemetry provides insights into the onset of this disease at a level not previously available, as shown in the plot below displaying the average and standard error measures across 11 rats. Following dosing, as indicated by the arrow and STZ abbreviation, blood glucose values increase as the beta cells are shocked and stop producing insulin. As the beta cells die and release all of their insulin, blood glucose drops. Over the next day, blood glucose increases again as significantly less insulin is being produced. The animal then achieves a new hyperglycemic homeostasis.